ANAB
ANAPTYSBIO, INC
NASDAQ · Healthcare · Biotechnology · US
$49.24
+5.64%Sep 21, 2026, 22:35 UTC
AnaptysBio, Inc. reported a Q2 loss of $0.11 per share, beating the Zacks Consensus Estimate of a $0.46 loss and improving from a $1.34 loss per share a year earlier.
Source:Sep 21, 2026, 20:15 UTC
AnaptysBio, Inc. reported its financial results for the second quarter and transitional fiscal year ended June 30, 2026, and provided a business update.
Source: